TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15265256
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) plus COM twice daily
Study: 9160758
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (180 mg)
Study: 9160758
Drug: Trandolapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (1 mg)
Study: 9160758
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR + Trandolapril (fixed combination)
Study: 7961013
Drug: Multileaf collimator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multileaf collimator combined with three-dimensional treatment planning
Study: 7961013
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with photons
Study: 29721715
Drug: No locoregional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No locoregional treatment (no-LRT)
Study: 9717015
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol (selective approach)
Study: 2921096
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Ro 16-6028
Study: 2921096
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg Ro 16-6028
Study: 2921096
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg Ro 16-6028
Study: 1168170
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated recombinant influenza vaccine (Alice strain) administered intranasally
Study: 1168170
Drug: Subcutaneous, inactivated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous, inactivated, bivalent influenza vaccine
Study: 31677046
Drug: Monthly lifestyle
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly lifestyle education program including advice on nutritional changes and physical activity enhancement.
Study: 31677046
Drug: Attention-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control group receiving monthly lectures on non-cardiovascular topics with verbal advice on healthy diet and exercise.
Study: 25982601
Drug: Dorzolamide, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide, three times daily for three weeks
Study: 25982601
Drug: Placebo, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, three times daily for three weeks
Study: 23952999
Drug: ivabradine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (15 mg/day for 50% of patients, 10 mg/day for 28%)
Study: 20948195
Drug: Intratympanic (IT)
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic (IT) methylprednisolone injection
Study: 20948195
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control (no treatment)
Study: 19637947
Drug: Fosamprenavir 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir 1400 mg once/day
Study: 19637947
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg once/day
Study: 19637947
Drug: Fosamprenavir 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir 1400 mg plus Atazanavir 400 mg once/day
Study: 16293317
Drug: Amoxicillin-clavulanate (45/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Study: 15156472
Drug: Echinacea purpurea,
Normalized name: Echinacea purpurea,angustif xt 125 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Study: 15156472
Drug: Placebo, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2.5 mL 3 times per day for 7 days before and 7 days after inoculation
Study: 11288041
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 g/kg body weight)
Study: 8323333
Drug: subcutaneous human
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous human recombinant erythropoietin (r‐HuEpo)
Study: 3090274
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pethidine and hyoscine butyl bromide
Study: 20042440
Drug: Gentler words
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentler words for administration of the local anesthetic
Study: 20042440
Drug: Harsher nocebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harsher nocebo words for administration of the local anesthetic
Study: 18378354
Drug: Terbinafine (5‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (5‐8 mg/kg)
Study: 18378354
Drug: Griseofulvin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (10‐20 mg/kg)
Study: 18378354
Drug: Terbinafine (5‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (5‐8 mg/kg) in trial 1
Study: 18378354
Drug: Griseofulvin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (10‐20 mg/kg) in trial 1
Study: 18378354
Drug: Terbinafine (5‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (5‐8 mg/kg) in trial 2
Study: 18378354
Drug: Griseofulvin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (10‐20 mg/kg) in trial 2
Study: 18378354
Drug: Terbinafine (5‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (5‐8 mg/kg) for T. tonsurans
Study: 18378354
Drug: Griseofulvin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (10‐20 mg/kg) for M. canis
Study: 7638926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Heparin and physical methods)
Study: 2692823
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (2 gm daily)
Study: 2692823
Drug: Clavulanate‐potentiated amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavulanate‐potentiated amoxicillin (1.125 gm daily)
Study: 31042621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list, no treatment, n = 25)
Study: 22964882
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) at a dose of 5 mg on day 1 of each course of low-dose Ara-C (LDAC)
Study: 22964882
Drug: Low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ara-C (LDAC) alone
Study: 22040189
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) at a target dose of 1.2 mg/kg/day for 8 weeks
Study: 19402154
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (75 mg/day for 2 months)
Study: 8875537
Drug: Low calorie/low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie/low fat intravenous solution (C)
Study: 6340444
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (5 mg)
Study: 22855917
Drug: Modified hypocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified hypocaloric diet (MHCD) with high-protein, low-glycemic load (30% of daily energy from protein)
Study: 22855917
Drug: Conventional hypocaloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypocaloric diet (CHCD) (15% of daily energy from protein)
Study: 15867002
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment (1 g vitamin C and 1 g vitamin E daily for 2 months)
Study: 12236630
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units subcutaneous IFN-alpha
Study: 31881911
Drug: Multimodal manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal manual therapy (MT) treatment
Study: 26891118
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150 μg of iodine as potassium iodate daily for 24 weeks)
Study: 19125778
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg and 25 mg
Study: 10522993
Drug: Ibandronate infusion
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate infusion (dosage not specified)
Study: 1659253
Drug: Esmolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.0 mg/kg)
Study: 1659253
Drug: Labetalol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.3 mg/kg)
Study: 1952135
Drug: Lidocaine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.0 mg/kg)
Study: 17709710
Drug: TCH346 (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH346 (1.0, 2.5, 7.5, or 15 mg/day)
Study: 8042757
Drug: flunitrazepam/fentanyl (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam/fentanyl (0.01 mg/kg for induction, 1.2 mg/h for maintenance)
Study: 8042757
Drug: etomidate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate (0.25 mg/kg) and fentanyl (0.005 mg/kg) for induction, isoflurane (0.6‐1.2 vol%)/fentanyl (1.2 mg/h) for maintenance
Study: 3381314
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antimalarial agents)
Study: 6353843
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid treatment
Study: 22623383
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (4 mg iron/L, 13.1 g protein/L)
Study: 17848393
Drug: ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (5 mg BID)
Study: 16392975
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy plus cognitive-behavioral (MET-CB) treatment
Study: 12399280
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake from diet plus supplements
Study: 12399280
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine excretion measured as a concentration
Study: 10467958
Drug: H2‐receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐receptor antagonist (n = 196)
Study: 10467958
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (n = 116)
Study: 7826063
Drug: UFT combined
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT combined therapy group (UFT, DESP, and castration)
Study: 7826063
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone group (DESP and castration)
Study: 1369703
Drug: Nicardipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60 mg daily)
Study: 7000228
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole
Study: 27759074
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg or 400 mg γδ‐T3 emulsions
Study: 26026286
Drug: Bromocriptine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine therapy (2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to 56) plus best supportive care (BSC)
Study: 26026286
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care (BSC) plus 1 week of low-dose bromocriptine (2.5 mg q.d.) with anticoagulant therapy at a prophylactic dose
Study: 23375680
Drug: DPP-IV inhibitors
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitors (sitagliptin and vildagliptin)
Study: 22443213
Drug: DPP-IV inhibitors
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitors
Study: 20553148
Drug: Amoxicillin antibiotic
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin antibiotic prophylaxis
Study: 20553148
Drug: Different amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different amoxicillin regimens
Study: 19436275
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication group receiving 1-week triple therapy (n=105)
Study: 31129930
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg
Study: 14993498
Drug: Citrate-taurolidine-containing solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-taurolidine-containing solution
Study: 11240235
Drug: Long-term hormones
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term hormones (LTH) - goserelin starting the last week of RT and continued indefinitely.
Study: 11240235
Drug: Short-term hormones
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term hormones (STH) - goserelin and flutamide 2 months prior to and during RT.
Study: 11240235
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone.
Study: 8070927
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluconazole orally over 5 days
Study: 8070927
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluconazole for 10-21 days
Study: 8070927
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluconazole
Study: 3281775
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg inhaled diltiazem
Study: 3281775
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg inhaled diltiazem
Study: 3281775
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg inhaled diltiazem
Study: 3281775
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg inhaled diltiazem
Study: 3281775
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg inhaled diltiazem
Study: 3281775
Drug: High-dose diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose diltiazem (20 to 45 mg)
Study: 27692976
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg once daily for 5 days
Study: 25608582
Drug: Deep breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep breathing test (DBT) + sequential standard BP measurement
Study: 25608582
Drug: Sequential standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential standard BP measurement only
Study: 23312003
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity Internet-delivered psychotherapy + improved treatment as usual (ITAU) by GP
Study: 21658716
Drug: Miglustat treatment
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat treatment
Study: 24276460
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg once weekly
Study: 15688961
Drug: Toothbrush without
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothbrush without antimicrobial agent (control)
Study: 9567620
Drug: Rokitamycin 800
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 800 mg/day
Study: 9567620
Drug: Rokitamycin 1200
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 1200 mg/day
Study: 8205303
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg/day)
Study: 3360340
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection to the antagonist, nonparalytic horizontal rectus muscle
Study: 3360340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no botulinum toxin treatment)
Study: 31958877
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pills (COCP) containing 20 mcg ethinyl estradiol/150 mg desogestrel for two continuous cycles
Study: 31958877
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAID); mefenamic acid 500 mg TDS for 5 days, 21 days apart for two cycles
Study: 27871076
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for 1 week pre-URS
Study: 25632646
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin 200 sg/kg body weight
Study: 25632646
Drug: Topical lindane
Normalized name: lindane Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lindane lotion 1% (two applications with a 1-week interval)
Study: 21511828
Drug: Pirfenidone 1200
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 1200 mg/d
Study: 21511828
Drug: Pirfenidone 2400
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 2400 mg/d
Study: 20598667
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intravitreal ranibizumab
Study: 20598667
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab
Study: 12014437
Drug: Non-Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Hormone Replacement Therapy (non-HRT)
Study: 20533545
Drug: Abatacept (∼10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (∼10 mg/kg of body weight)
Study: 9477021
Drug: Full-mouth disinfection
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth disinfection (scaling and rootplaning of all pockets in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation of all pockets with 1% chlorhexidine gel 3x in 10 min, rinsing 2x daily with 0.2% chlorhexidine, spraying tonsils with 0.2% chlorhexidine for 2 months)
Study: 9477021
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (scaling and rootplaning per quadrant at 2-week intervals, oral hygiene instructions)
Study: 27606616
Drug: Körpertambura treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Körpertambura treatment (10-minute session)
Study: 20479425
Drug: Cisplatin (CIS)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CIS) 100 mg/m(2) on day 1 of weeks 1, 4, and 7
Study: 20479425
Drug: Cisplatin (CIS)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CIS) 75 mg/m(2) plus Tirapazamine (TPZ) 290 mg/m(2)/d on day 1 of weeks 1, 4, and 7 and TPZ alone 160 mg/m(2)/d on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS)
Study: 18410547
Drug: LT4-LT3 combination
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4-LT3 combination therapy
Study: 15634723
Drug: Oral vitamin-B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vitamin-B and folic acid therapy (n = 27)
Study: 12879814
Drug: Spiron (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiron (local formulation of risperidone)
Study: 12879814
Drug: Risperdal (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperdal (original formulation of risperidone)
Study: 2651174
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg/day
Study: 3905218
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day
Study: 28332859
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 mL) in 2 mL normal saline
Study: 8922004
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (4 mL)
Study: 22957434
Drug: Osmotic pump
Normalized name: Ez2go Osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic pump tablets with EC/PVP K30
Study: 17564561
Drug: Cockcroft-Gault (C-G)
Normalized name: Gaultheria procumbens top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockcroft-Gault (C-G)
Study: 7840507
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen 20 mg once daily for two years
Study: 2849717
Drug: Acyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (500 mg/m² IV every 8 hours for 7 days, followed by 800 mg orally four times daily for 30 days)
Study: 2849717
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous placebo for 7 days, followed by oral placebo for 30 days)